進化し続ける医学の進歩の分野では、てんかん治療におけるイニシアチブとイノベーションが、患者ケアのパラダイムを再構築する上で極めて重要な役割を果たしています。世界的には、政府が支援する取り組みと医薬品や治療法の最先端の開発により、てんかん治療市場は前例のない成長を遂げています。注目すべき取り組みは、2022 年 2 月に NYU Langone Health が米国国立衛生研究所 (NIH) から 800 万ドルの助成金を獲得したことで発生しました。この資金は、発作中の脳活動に関する前例のないデータを取得するように設計された革新的な埋め込み型モニタリングデバイスの開発に充てられます。NYU Langoneの総合てんかんセンターのダニエル・フリードマン博士が率いるこのプロジェクトは、時代遅れの技術の限界に対処し、数千の測定接点を備えた超薄型デバイスを構築する機会を提供します。NIH UG3/UH3が資金提供するこのイニシアチブには、ニューヨーク大学の神経科学センター、デューク大学、ユタ大学、ブラックロック・ニューロテックなどの機関とのコラボレーションが含まれます。
目次
1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Epilepsy Therapeutics Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Transforming Brain Tumour-Related Epilepsy through Innovative Gene Therapy Approaches
3.2.1.2 Uncovering Novel Possibilities in a Rare Form of Childhood Epilepsy Treatment
3.2.1.3 Advancements, Global Investments, and Medical Advances Drive Epilepsy Treatment Market Growth
3.2.1.4 Surge in Epilepsy Prevalence
3.2.2 Market Restraining Factors
3.2.2.1 Seizure Recognition Challenges
3.2.2.2 Socioeconomic Disparities and Technological Challenges
3.2.2.3 Patent Expiry
3.2.3 Market Opportunities
3.2.3.1 Innovating Antiepileptic Therapies for Drug-Resistant Cases
3.2.3.2 Inhibitory Neurons Transform Focal Epilepsy Treatment
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis
4 Epilepsy Therapeutics Market Analysis by Drug Class
4.1 Key Findings
4.2 Drug Class Segment: Market Attractiveness Index
4.3 Epilepsy Therapeutics Market Size Estimation and Forecast by Drug Class
4.4 First Generation Drugs
4.4.1 Market Size by Region, 2024-2034 (US$ Million)
4.4.2 Market Share by Region, 2024 & 2034 (%)
4.5 Second Generation Drugs
4.5.1 Market Size by Region, 2024-2034 (US$ Million)
4.5.2 Market Share by Region, 2024 & 2034 (%)
4.6 Third Generation Drugs
4.6.1 Market Size by Region, 2024-2034 (US$ Million)
4.6.2 Market Share by Region, 2024 & 2034 (%)
5 Epilepsy Therapeutics Market Analysis by Distribution Channel
5.1 Key Findings
5.2 Distribution Channel Segment: Market Attractiveness Index
5.3 Epilepsy Therapeutics Market Size Estimation and Forecast by Distribution Channel
5.4 Hospital Pharmacy
5.4.1 Market Size by Region, 2024-2034 (US$ Million)
5.4.2 Market Share by Region, 2024 & 2034 (%)
5.5 Retail Pharmacy
5.5.1 Market Size by Region, 2024-2034 (US$ Million)
5.5.2 Market Share by Region, 2024 & 2034 (%)
5.6 Online Pharmacy
5.6.1 Market Size by Region, 2024-2034 (US$ Million)
5.6.2 Market Share by Region, 2024 & 2034 (%)
6 Epilepsy Therapeutics Market Analysis by Region
6.1 Key Findings
6.2 Regional Market Size Estimation and Forecast
7 North America Epilepsy Therapeutics Market Analysis
7.1 Key Findings
7.2 North America Epilepsy Therapeutics Market Attractiveness Index
7.3 North America Epilepsy Therapeutics Market by Country, 2024, 2029 & 2034 (US$ Million)
7.4 North America Epilepsy Therapeutics Market Size Estimation and Forecast by Country
7.5 North America Epilepsy Therapeutics Market Size Estimation and Forecast by Drug Class
7.6 North America Epilepsy Therapeutics Market Size Estimation and Forecast by Distribution Channel
7.7 U.S. Epilepsy Therapeutics Market Analysis
7.8 Canada Epilepsy Therapeutics Market Analysis
8 Europe Epilepsy Therapeutics Market Analysis
8.1 Key Findings
8.2 Europe Epilepsy Therapeutics Market Attractiveness Index
8.3 Europe Epilepsy Therapeutics Market by Country, 2024, 2029 & 2034 (US$ Million)
8.4 Europe Epilepsy Therapeutics Market Size Estimation and Forecast by Country
8.5 Europe Epilepsy Therapeutics Market Size Estimation and Forecast by Drug Class
8.6 Europe Epilepsy Therapeutics Market Size Estimation and Forecast by Distribution Channel
8.7 Germany Epilepsy Therapeutics Market Analysis
8.8 France Epilepsy Therapeutics Market Analysis
8.9 UK Epilepsy Therapeutics Market Analysis
8.10 Italy Epilepsy Therapeutics Market Analysis
8.11 Spain Epilepsy Therapeutics Market Analysis
8.12 Sweden Epilepsy Therapeutics Market Analysis
8.13 Switzerland Epilepsy Therapeutics Market Analysis
8.14 Rest of Europe Epilepsy Therapeutics Market Analysis
9 Asia Pacific Epilepsy Therapeutics Market Analysis
9.1 Key Findings
9.2 Asia Pacific Epilepsy Therapeutics Market Attractiveness Index
9.3 Asia Pacific Epilepsy Therapeutics Market by Country, 2024, 2029 & 2034 (US$ Million)
9.4 Asia Pacific Epilepsy Therapeutics Market Size Estimation and Forecast by Country
9.5 Asia Pacific Epilepsy Therapeutics Market Size Estimation and Forecast by Drug Class
9.6 Asia Pacific Epilepsy Therapeutics Market Size Estimation and Forecast by Distribution Channel
9.7 Japan Epilepsy Therapeutics Market Analysis
9.8 China Epilepsy Therapeutics Market Analysis
9.9 India Epilepsy Therapeutics Market Analysis
9.10 Australia Epilepsy Therapeutics Market Analysis
9.11 South Korea Epilepsy Therapeutics Market Analysis
9.12 Singapore Epilepsy Therapeutics Market Analysis
9.13 Taiwan Epilepsy Therapeutics Market Analysis
9.14 Rest of Asia Pacific Epilepsy Therapeutics Market Analysis
10 Latin America Epilepsy Therapeutics Market Analysis
10.1 Key Findings
10.2 Latin America Epilepsy Therapeutics Market Attractiveness Index
10.3 Latin America Epilepsy Therapeutics Market by Country, 2024, 2029 & 2034 (US$ Million)
10.4 Latin America Epilepsy Therapeutics Market Size Estimation and Forecast by Country
10.5 Latin America Epilepsy Therapeutics Market Size Estimation and Forecast by Drug Class
10.6 Latin America Epilepsy Therapeutics Market Size Estimation and Forecast by Distribution Class
10.7 Brazil Epilepsy Therapeutics Market Analysis
10.8 Mexico Epilepsy Therapeutics Market Analysis
10.9 Argentina Epilepsy Therapeutics Market Analysis
10.10 Rest of Latin America Epilepsy Therapeutics Market Analysis
11 MEA Epilepsy Therapeutics Market Analysis
11.1 Key Findings
11.2 MEA Epilepsy Therapeutics Market Attractiveness Index
11.3 MEA Epilepsy Therapeutics Market by Country, 2024, 2029 & 2034 (US$ Million)
11.4 MEA Epilepsy Therapeutics Market Size Estimation and Forecast by Country
11.5 MEA Epilepsy Therapeutics Market Size Estimation and Forecast by Drug Class
11.6 MEA Epilepsy Therapeutics Market Size Estimation and Forecast by Application
11.7 GCC Epilepsy Therapeutics Market Analysis
11.8 South Africa Epilepsy Therapeutics Market Analysis
11.9 Rest of MEA Epilepsy Therapeutics Market Analysis
12 Company Profiles
12.1 Competitive Landscape, 2022
12.2 Strategic Outlook
12.1 Eisai, Inc.
12.1.1 Company Snapshot
12.1.2 Company Overview
12.1.3 Financial Analysis
12.1.3.1 Net Revenue, 2017-2022
12.1.3.2 Regional Market Shares, 2022
12.1.4 Product Benchmarking
12.1.5 Strategic Outlook
12.2 GlaxoSmithKline (GSK)
12.2.1 Company Snapshot
12.2.2 Company Overview
12.2.3 Financial Analysis
12.2.3.1 Net Revenue, 2017-2022
12.2.3.2 R&D, 2017-2022
12.2.3.3 Regional Market Shares, 2022
12.2.4 Product Benchmarking
12.2.5 Strategic Outlook
12.3 GW Pharma
12.3.1 Company Snapshot
12.3.2 Company Overview
12.3.3 Product Benchmarking
12.3.4 Strategic Outlook
12.4 Pfizer Inc
12.4.1 Company Snapshot
12.4.2 Company Overview
12.4.3 Financial Analysis
12.4.3.1 Net Revenue, 2017-2022
12.4.3.2 R&D, 2017-2022
12.4.3.3 Regional Market Shares, 2022
12.4.4 Product Benchmarking
12.4.5 Strategic Outlook
12.5 Sanofi
12.5.1 Company Snapshot
12.5.2 Company Overview
12.5.3 Financial Analysis
12.5.3.1 Net Revenue, 2017-2022
12.5.3.2 R&D, 2017-2022
12.5.3.3 Regional Market Shares, 2022
12.5.4 Product Benchmarking
12.5.5 Strategic Outlook
12.6 UCB S.A.
12.6.1 Company Snapshot
12.6.2 Company Overview
12.6.3 Financial Analysis
12.6.3.1 Net Revenue, 2017-2022
12.6.3.2 R&D, 2017-2022
12.6.3.3 Regional Market Shares, 2022
12.6.4 Product Benchmarking
12.6.5 Strategic Outlook
12.7 Novartis AG
12.7.1 Company Snapshot
12.7.2 Company Overview
12.7.3 Financial Analysis
12.7.3.1 Net Revenue, 2017-2022
12.7.3.2 R&D, 2017-2022
12.7.3.3 Regional Market Shares, 2022
12.7.4 Product Benchmarking
12.7.5 Strategic Outlook
12.8 Merck KGaA
12.8.1 Company Snapshot
12.8.2 Company Overview
12.8.3 Financial Analysis
12.8.3.1 Net Revenue, 2017-2022
12.8.3.2 R&D, 2017-2022
12.8.3.3 Regional Market Shares, 2022
12.8.4 Product Benchmarking
12.8.5 Strategic Outlook
12.9 Ovid Therapeutics
12.9.1 Company Snapshot
12.9.2 Company Overview
12.9.3 Product Benchmarking
12.9.4 Strategic Outlook
12.10 Praxis Precision Medicines
12.10.1 Company Snapshot
12.10.2 Company Overview
12.10.3 Product Benchmarking
12.10.4 Strategic Outlook
12.11 Neurocrine Biosciences, Inc.
12.11.1 Company Snapshot
12.11.2 Company Overview
12.11.3 Financial Analysis
12.11.3.1 Net Revenue, 2017-2022
12.11.3.2 R&D, 2017-2022
12.11.4 Product Benchmarking
12.11.5 Strategic Outlook
12.12 Neurelis, Inc.
12.12.1 Company Snapshot
12.12.2 Company Overview
12.12.3 Product Benchmarking
12.12.4 Strategic Outlook
13 Conclusion and Recommendations
13.1 Concluding Remarks from Visiongain
13.2 Recommendations for Market Players
?
List of Tables
Table 1 Epilepsy Therapeutics Market Snapshot, 2024 & 2034 (US$ million, CAGR %)
Table 2 Epilepsy Therapeutics Market Forecast by Region 2024-2034 (US$ Million, AGR%, CAGR%): "V" Shaped Recovery
Table 3 Epilepsy Therapeutics Market Forecast by Region 2024-2034 (US$ Million, AGR%, CAGR%): "U" Shaped Recovery
Table 4 Epilepsy Therapeutics Market Forecast by Region 2024-2034 (US$ Million, AGR%, CAGR%): "W" Shaped Recovery
Table 5 Epilepsy Therapeutics Market Forecast by Region 2024-2034 (US$ Million, AGR%, CAGR%): "L" Shaped Recovery
Table 6 Epilepsy Therapeutics Market Forecast by Drug Class, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 7 First Generation Drugs Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 8 Second Generation Drugs Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 9 Third Generation Drugs Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 10 Epilepsy Therapeutics Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 11 Hospital Pharmacy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 12 Retail Pharmacy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 13 Online Pharmacy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 14 Epilepsy Therapeutics Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 15 North America Epilepsy Therapeutics Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 16 North America Epilepsy Therapeutics Market Forecast by Drug Class, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 17 North America Epilepsy Therapeutics Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 18 U.S. Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 19 Canada Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 20 Europe Epilepsy Therapeutics Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 21 Europe Epilepsy Therapeutics Market Forecast by Drug Class, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 22 North America Epilepsy Therapeutics Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 23 Germany Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 24 France Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 25 UK Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 26 Italy Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 27 Spain Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 28 Sweden Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 29 Switzerland Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 30 Rest of Europe Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 31 Asia Pacific Epilepsy Therapeutics Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 32 Asia Pacific Epilepsy Therapeutics Market Forecast by Drug Class, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 33 Asia Pacific Epilepsy Therapeutics Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 34 Japan Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 35 China Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 36 India Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 37 Australia Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 38 South Korea Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 39 Singapore Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 40 Taiwan Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 41 Rest of Asia Pacific Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 42 Latin America Epilepsy Therapeutics Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 43 Latin America Epilepsy Therapeutics Market Forecast by Drug Class, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 44 Latin America Epilepsy Therapeutics Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 45 Brazil Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 46 Mexico Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 47 Argentina Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 48 Rest of Latin America Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 49 MEA Epilepsy Therapeutics Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 50 MEA Epilepsy Therapeutics Market Forecast by Drug Class, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 51 MEA Epilepsy Therapeutics Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 52 GCC Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 53 South Africa Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 54 Rest of MEA Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 55 Strategic Outlook
Table 56 Eisai, Inc. : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 57 Eisai, Inc.: Product Benchmarking
Table 58 Eisai, Inc.: Strategic Outlook
Table 59 GlaxoSmithKline (GSK): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 60 GlaxoSmithKline (GSK): Product Benchmarking
Table 61 GlaxoSmithKline (GSK): Strategic Outlook
Table 62 GW Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 63 GW Pharma : Product Benchmarking
Table 64 GW Pharma : Strategic Outlook
Table 65 Pfizer Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 66 Pfizer Inc : Product Benchmarking
Table 67 Pfizer Inc: Strategic Outlook
Table 68 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 69 Sanofi: Product Benchmarking
Table 70 Sanofi: Strategic Outlook
Table 71 UCB S.A.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 72 UCB S.A.: Product Benchmarking
Table 73 UCB S.A.: Strategic Outlook
Table 74 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 75 Novartis AG: Product Benchmarking
Table 76 Novartis AG: Strategic Outlook
Table 77 Merck KGaA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 78 Merck KGaA: Product Benchmarking
Table 79 Merck KGaA: Strategic Outlook
Table 80 Ovid Therapeutics : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 81 Ovid Therapeutics : Product Benchmarking
Table 82 Ovid Therapeutics: Strategic Outlook
Table 83 Praxis Precision Medicines: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 84 Praxis Precision Medicines: Product Benchmarking
Table 85 Praxis Precision Medicines: Strategic Outlook
Table 86 Neurocrine Biosciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 87 Neurocrine Biosciences, Inc.: Product Benchmarking
Table 88 Neurocrine Biosciences, Inc.: Strategic Outlook
Table 89 Neurelis, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 Neurelis, Inc.: Product Benchmarking
Table 91 Neurelis, Inc.: Strategic Outlook
?
List of Figures
Figure 1 Epilepsy Therapeutics Market Segmentation
Figure 2 Epilepsy Therapeutics Market by Drug Class: Market Attractiveness Index
Figure 3 Epilepsy Therapeutics Market by Distribution Channel: Market Attractiveness Index
Figure 4 Epilepsy Therapeutics Market Attractiveness Index by Region
Figure 5 Epilepsy Therapeutics Market: Market Dynamics
Figure 6 Epilepsy Therapeutics Market by Region, 2024-2034 (US$ Million, AGR %): “V” Shaped Recovery
Figure 7 Epilepsy Therapeutics Market by Region, 2024-2034 (US$ Million, AGR %): “U” Shaped Recovery
Figure 8 Epilepsy Therapeutics Market by Region, 2024-2034 (US$ Million, AGR %): “W” Shaped Recovery
Figure 9 Epilepsy Therapeutics Market by Region, 2024-2034 (US$ Million, AGR %): “L” Shaped Recovery
Figure 10 Epilepsy Therapeutics Market: Porter’s Five Forces Analysis
Figure 11 Epilepsy Therapeutics Market: PEST Analysis
Figure 12 Epilepsy Therapeutics Market by Drug Class: Market Attractiveness Index
Figure 13 Epilepsy Therapeutics Market Forecast by Drug Class, 2024-2034 (US$ Million, AGR %)
Figure 14 Epilepsy Therapeutics Market Share Forecast by Drug Class, 2024, 2029, 2034 (%)
Figure 15 First Generation Drugs Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 16 First Generation Drugs Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 17 Second Generation Drugs Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 18 Second Generation Drugs Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 19 Third Generation Drugs Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 20 Third Generation Drugs Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 21 Epilepsy Therapeutics Market by Distribution Channel: Market Attractiveness Index
Figure 22 Epilepsy Therapeutics Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 23 Epilepsy Therapeutics Market Share Forecast by Distribution Channel, 2024, 2029, 2034 (%)
Figure 24 Hospital Pharmacy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 25 Hospital Pharmacy Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 26 Retail Pharmacy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 27 Retail Pharmacy Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 28 Online Pharmacy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 29 Online Pharmacy Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 30 Epilepsy Therapeutics Market Forecast by Region 2024 and 2034 (Revenue, CAGR%)
Figure 31 Epilepsy Therapeutics Market Share Forecast by Region 2024, 2029, 2034 (%)
Figure 32 Epilepsy Therapeutics Market by Region, 2024-2034 (US$ Million, AGR %)
Figure 33 North America Epilepsy Therapeutics Market Attractiveness Index
Figure 34 North America Epilepsy Therapeutics Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 35 North America Epilepsy Therapeutics Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 36 North America Epilepsy Therapeutics Market Share Forecast by Country, 2024 & 2034 (%)
Figure 37 North America Epilepsy Therapeutics Market Forecast by Drug Class, 2024-2034 (US$ Million, AGR %)
Figure 38 North America Epilepsy Therapeutics Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 39 North America Epilepsy Therapeutics Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 40 North America Epilepsy Therapeutics Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 41 U.S. Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 42 Canada Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 43 Europe Epilepsy Therapeutics Market Attractiveness Index
Figure 44 Europe Epilepsy Therapeutics Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 45 Europe Epilepsy Therapeutics Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 46 Europe Epilepsy Therapeutics Market Share Forecast by Country, 2024 & 2034 (%)
Figure 47 Europe Epilepsy Therapeutics Market Forecast by Drug Class, 2024-2034 (US$ Million, AGR %)
Figure 48 Europe Epilepsy Therapeutics Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 49 Europe Epilepsy Therapeutics Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 50 Europe Epilepsy Therapeutics Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 51 Germany Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 52 France Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 53 UK Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 54 Italy Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 55 Spain Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 56 Sweden Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 57 Switzerland Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 58 Rest of Europe Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 59 Asia Pacific Epilepsy Therapeutics Market Attractiveness Index
Figure 60 Asia Pacific Epilepsy Therapeutics Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 61 Asia Pacific Epilepsy Therapeutics Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 62 Asia Pacific Epilepsy Therapeutics Market Share Forecast by Country, 2024 & 2034 (%)
Figure 63 Asia Pacific Epilepsy Therapeutics Market Forecast by Drug Class, 2024-2034 (US$ Million, AGR %)
Figure 64 Asia Pacific Epilepsy Therapeutics Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 65 Asia Pacific Epilepsy Therapeutics Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 66 Asia Pacific Epilepsy Therapeutics Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 67 Japan Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 68 China Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 69 India Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 70 Australia Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 71 South Korea Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 72 Singapore Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 73 Taiwan Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 74 Rest of Asia Pacific Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 75 Latin America Epilepsy Therapeutics Market Attractiveness Index
Figure 76 Latin America Epilepsy Therapeutics Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 77 Latin America Epilepsy Therapeutics Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 78 Latin America Epilepsy Therapeutics Market Share Forecast by Country, 2024 & 2034 (%)
Figure 79 Latin America Epilepsy Therapeutics Market Forecast by Drug Class, 2024-2034 (US$ Million, AGR %)
Figure 80 Latin America Epilepsy Therapeutics Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 81 Latin America Epilepsy Therapeutics Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 82 Latin America Epilepsy Therapeutics Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 83 Brazil Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 84 Mexico Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 85 Argentina Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 86 Rest of Latin America Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 87 MEA Epilepsy Therapeutics Market Attractiveness Index
Figure 88 MEA Epilepsy Therapeutics Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 89 MEA Epilepsy Therapeutics Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 90 MEA Epilepsy Therapeutics Market Share Forecast by Country, 2024 & 2034 (%)
Figure 91 MEA Epilepsy Therapeutics Market Forecast by Drug Class, 2024-2034 (US$ Million, AGR %)
Figure 92 MEA Epilepsy Therapeutics Market Share Forecast by Drug Class, 2024 & 2034 (%)
Figure 93 MEA Epilepsy Therapeutics Market Forecast by Distribution Channel, 2024-2034 (US$ Million, AGR %)
Figure 94 MEA Epilepsy Therapeutics Market Share Forecast by Distribution Channel, 2024 & 2034 (%)
Figure 95 GCC Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 96 South Africa Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 97 Rest of MEA Epilepsy Therapeutics Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 98 Eisai, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 99 Eisai, Inc.: Regional Market Shares, 2022
Figure 100 GlaxoSmithKline (GSK): Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 101 GlaxoSmithKline (GSK): R&D, 2017-2022 (US$ Million, AGR%)
Figure 102 GlaxoSmithKline (GSK): Regional Market Shares, 2022
Figure 103 Pfizer Inc: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 104 Pfizer Inc: R&D, 2017-2022 (US$ Million, AGR%)
Figure 105 Pfizer Inc: Regional Market Shares, 2022
Figure 106 Sanofi: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 107 Sanofi: R&D, 2017-2022 (US$ Million, AGR%)
Figure 108 Sanofi: Regional Market Shares, 2022
Figure 109 UCB S.A.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 110 UCB S.A.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 111 UCB S.A.: Regional Market Shares, 2022
Figure 112 Novartis AG: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 113 Novartis AG: R&D, 2017-2022 (US$ Million, AGR%)
Figure 114 Novartis AG: Regional Market Shares, 2022
Figure 115 Merck KGaA: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 116 Merck KGaA: R&D, 2017-2022 (US$ Million, AGR%)
Figure 117 Merck KGaA: Regional Market Shares, 2022
Figure 118 Neurocrine Biosciences Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 119 Neurocrine Biosciences Inc.: R&D, 2017-2022 (US$ Million, AGR%)
